Eli Lilly
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after the company report...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a c...
Latest News
12 hours ago · gurufocus.com
Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical AntibodyEli Lilly and Co. (LLY) agreed to acquire Calytrix Bio for up to $1.5 billion in cash. The total includes an upfront payment and further payments tied to clinic
13 hours ago · wsj.com
Eli Lilly to Buy Calytrix Bio for Up to $1.5 BillionCalytrix Bio, a privately held biotechnology company backed by JPMorgan Chase, is developing therapies aimed at a group of rare blood cancers.
15 hours ago · zacks.com
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should KnowLilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
1 day ago · fool.com
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027Eli Lilly is surging, with revenue up 39% in the third quarter and a retatrutide filing planned for early 2027. Novo is bouncing back on oral Wegovy, with a CagriSema decision due soon.
3 days ago · reuters.com
Mapping the Market: Eli Lilly shares ready to rally againMapping the Market: Eli Lilly shares ready to rally again
4 days ago · prnewswire.com
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobs INDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today broke ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley. The site is one of 10 new U.S. manufacturing sites announced since 2020 and one of four among them dedicated to injectable medicines and devices.
4 days ago · fool.com
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on ItAI could improve the drug discovery and development process. Eli Lilly has made an important move to benefit from this.
4 days ago · reuters.com
China approves Eli Lilly's weight loss pill orforglipronChina approves Eli Lilly's weight loss pill orforglipron
5 days ago · benzinga.com
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up HeatThe next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposure and Merck & Co‘s (NYSE:MRK) and Bristol-Myers Squibb Co‘s (NYSE:BMY) confronting a potentially bigger test in the years ahead.
5 days ago · prnewswire.com
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesityNearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LLY